Overview

Trial Comparing Capecitabine Plus Oxaliplatin (XELOX) and Capecitabine (X) as First-line Chemotherapy in Elderly Patients With Advanced Gastric Cancer

Status:
Withdrawn

Trial end date:
2015-12-01

Target enrollment:

Participant gender:

Summary

The objective of the trial is to compare Overall survival between capecitabine plus oxaliplatin (XELOX) and capecitabine (X) as first-line chemotherapy in elderly patients with advanced gastric cancer.

Phase:

Phase 3

Details

Lead Sponsor:

Samsung Medical Center

Treatments:

Capecitabine
Oxaliplatin